Previous 10 | Next 10 |
home / stock / agnpf / agnpf news
VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, announces that it has reach...
Algernon Pharmaceuticals (AGNPF) announces that it will not be advancing Ifenprodil into a Phase 3 clinical study for COVID-19.The decision was based on several factors including the overall findings of the Phase 2b COVID-19 study final data set, the global rate of vaccinations to date, other...
VANCOUVER, British Columbia, July 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, announces that it will not be advancing...
Algernon Pharmaceuticals (AGNPF) announces that all of the required permits and licenses for the manufacture of its cGMP supply of AP-188 (“N, N-Dimethyltryptamine or DMT”) have been received and as a result, is targeting its Phase 1 human study to be conducted at Hammersmith Me...
VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all of the required permits and licenses for the manufacture of ...
Algernon Pharmaceuticals (AGNPF) has initiated a new clinical research program for pancreatic cancer ((PC)) and NP-120 (Ifenprodil).Ifenprodil demonstrated a significant anti-tumour effect in a PC animal model which was reported in a paper published in the Dove Press Journal, Clinical Ph...
VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has initiated a new clinical research program for pancreatic cancer (PC) and NP...
Algernon is a Canada-based pharmaceutical company that seeks to repurpose previously approved drugs. The company's lead candidate is called Ifenprodil, which they are exploring to treat pulmonary fibrosis and chronic cough. Recently, they also announced pre-clinical data using the...
Algernon Pharmaceuticals (AGNPF) highlights an independent research study from the University of Szeged in Hungary describing the use of N,N-dimethyltryptamine (“DMT”), a known psychedelic compound that is part of the tryptamine family, in improving outcomes ...
VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an independent research study from the University of Szeged in Hungar...
News, Short Squeeze, Breakout and More Instantly...
Algernon Pharmaceuticals Inc - Class A Company Name:
AGNPF Stock Symbol:
OTCMKTS Market:
Algernon Pharmaceuticals Inc - Class A Website:
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report that ifenprodil achieved...
VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its...